Table 2.

Prognostic association of high SAMHD1 expression level in 17 major cancer types

P-values	Prognosis	Cancer type
0.007	Favorable	Cervical cancer
0.016	Favorable	Colorectal cancer
0.019	Favorable	Head and neck cancer
0.032	Favorable	Thyroid cancer
0.038	Favorable	Endometrial cancer
0.041	Favorable	Lung cancer
0.104	Favorable	Prostate cancer
0.109	Favorable	Breast cancer
0.128	Favorable	Glioma
0.203	Favorable	Melanoma
0.001	Unfavorable	Renal cancer
0.027	Unfavorable	Urothelial cancer
0.091	Unfavorable	Testis cancer
0.144	Unfavorable	Stomach cancer
0.188	Unfavorable	Pancreatic cancer
0.215	Unfavorable	Liver cancer
0.363	Unfavorable	Ovarian cancer

Results of the study [107] were used to compile the table depicting the prognostic association of SAMHD1 expression level in reported cancers. In the study, the transcriptomes of 17 major cancer types were analyzed with respect to clinical outcome to explore the prognostic role of each protein-coding gene in each cancer type. For each gene and cancer type, the patient cohort was stratified into two groups based on individual expression levels. The data included transcript expression levels summarized per gene (fragments per kilobase of exon per million mapped reads — FPKMs) in 7932 samples from 17 different cancer types. To choose the best FPKM cutoffs for grouping the patients for SAMHD1 most significantly, all FPKM values from the 20th to 80th percentiles were used here in testing for differences in the survival outcomes of the groups, and the FPKM value yielding the lowest log-rank P value was selected. Two types of prognostic genes affecting patient survival were defined: (i) SAMHD1 as an unfavorable prognostic gene, for which higher expression was correlated with a poor patient survival outcome, and (ii) SAMHD1 as a favorable prognostic gene, for which higher expression was correlated with a longer survival